Sept 24 (Reuters) - Sanofi has received two

separate bids for its consumer health unit, which could be

valued at 15 billion euros ($16.74 billion) or more, from

private equity firms Clayton Dubilier & Rice and PAI Partners,

Bloomberg News reported on Tuesday.

The drugmaker could decide to pursue a spinoff of the

business if the bids aren't attractive, Bloomberg said, citing

people familiar to the matter.

PAI is seeking to rope in British Columbia Investment

Management Corp. to back its bid. It has also been in talks to

bring Abu Dhabi Investment Authority and Singapore sovereign

fund GIC Pte into the consortium, the report added.

As announced in October 2023, Sanofi is reviewing potential

separation scenarios for its consumer healthcare business with a

transaction in the fourth quarter at the earliest, a Sanofi

spokesperson told Reuters.

No decision has been made yet and we expect to select the

best option for Sanofi and its stakeholders in the next few

months, the spokesperson also said.

($1 = 0.8962 euros)